SAVA Cassava Sciences

Cassava Sciences to Hold Corporate Update on November 25th

Cassava Sciences to Hold Corporate Update on November 25th

Webcast planned for Monday, November 25th at 8:00 AM ET

AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.

  
Event Details:
  
Date: Monday, November 25th
Time: 8:00 a.m. Eastern Time
Webcast:
  

A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.

Simufilam is an investigational oral, small molecule drug candidate currently being evaluated in two Phase 3 clinical trials for the potential treatment of Alzheimer's disease. Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.

For more information, please visit:

For More Information Contact:

Investors

Sandya von der Weid

Media

Company

Eric Schoen, Chief Financial Officer

(512) 501-2450

 



EN
25/11/2024

Underlying

SAVACassava Sciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cassava Sciences

 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Provides a Business Update

Cassava Sciences Provides a Business Update Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment including a workforce reduction of approximately 33% Approximately $128.6 million cash and cash equivalents at December 31, 2024 (unaudited) AUSTIN, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatme...

January 7, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTSH Tile Shop Holdi...
PSEC Prospect Capita... ... (+11)

InsiderInsights.com Daily Ratings Report: December 3, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
PSEC PROSPECT CAPITAL CORPORATION
FCN FTI CONSULTING INC.
BRKR BRUKER CORPORATION
GTN GRAY TELEVISION INC.
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
SAVA CASSAVA SCIENCES
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
BIGZ BLACKROCK INNOVATION AND GROWTH TST
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
EVM EATON VANCE INSD CALIF MUN BD FD
12/04/24 December 4, 2024 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoint...

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in the ReThink-ALZ Phase 3 study Simufilam continued to demonstrate an overall favorable safety profile Cassava intends to present the data at an upcoming medical meeting The Company will hold a webcast today, November 25, 2024, at 8:00 AM ET AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Comp...

November 25, 2024 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences to Hold Corporate Update on November 25th

Cassava Sciences to Hold Corporate Update on November 25th Webcast planned for Monday, November 25th at 8:00 AM ET AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.    Event Details:    Date: Monday, November 25th Time: 8:00 a.m. Eastern Time Webcast:    A replay of the audio webcast will also be available on the Company P...

November 25, 2024 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava’s commercial readiness strategy as the Company prepares for first Phase 3 topline data readout before year end 2024 AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today announced the appointment of Freda Nassif as Chief Commer...

November 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch